These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23989980)

  • 1. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
    Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
    Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
    Yan SB; Peek VL; Ajamie R; Buchanan SG; Graff JR; Heidler SA; Hui YH; Huss KL; Konicek BW; Manro JR; Shih C; Stewart JA; Stewart TR; Stout SL; Uhlik MT; Um SL; Wang Y; Wu W; Yan L; Yang WJ; Zhong B; Walgren RA
    Invest New Drugs; 2013 Aug; 31(4):833-44. PubMed ID: 23275061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
    Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
    Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
    Barat S; Bozko P; Chen X; Scholta T; Hanert F; Götze J; Malek NP; Wilkens L; Plentz RR
    Mol Carcinog; 2016 Dec; 55(12):2037-2050. PubMed ID: 26757360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
    Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
    Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
    Shi W; Song J; Wang W; Zhang Y; Zheng S
    Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
    Coxon A; Ziegler B; Kaufman S; Xu M; Wang H; Weishuhn D; Schmidt J; Sweet H; Starnes C; Saffran D; Polverino A
    Mol Cancer; 2012 Sep; 11():70. PubMed ID: 22992329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
    Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
    J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.